9月3日,舶望制药宣布与诺华达成一项新战略合作协议,双方共同开发多项心血管产品。根据协议,舶望制药授予诺华两款处于早研阶段分子的中国以外权益的选择权,用于治疗重度高甘油三酯血症(sHTG)和混合型血脂异常;BW-00112(ANGPTL3)产品的优先谈判权,该产品目前在美国和中国处于2期临床阶段,后续将由舶望制药主导开展联合用药的临床试验;针对另一款处于临床前研究阶段的siRNA候选药物的中国外...
Source Link9月3日,舶望制药宣布与诺华达成一项新战略合作协议,双方共同开发多项心血管产品。根据协议,舶望制药授予诺华两款处于早研阶段分子的中国以外权益的选择权,用于治疗重度高甘油三酯血症(sHTG)和混合型血脂异常;BW-00112(ANGPTL3)产品的优先谈判权,该产品目前在美国和中国处于2期临床阶段,后续将由舶望制药主导开展联合用药的临床试验;针对另一款处于临床前研究阶段的siRNA候选药物的中国外...
Source LinkDisclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.